Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors

Transplant Infectious Disease

Volumn 13, Issue 3, 2011, Pages 318-323

  Ishibashi, Kei ^a   Tokumoto, T ^b   Shirakawa, H ^b   Hashimoto, K ^a   Ikuta, K ^a   Kushida, N ^a   Yanagida, T ^a   Shishido, K ^a   Aikawa, K ^a   Toma, H ^b   Inoue, N ^c   Yamaguchi, O ^a   Tanabe, K ^b   Suzutani, T ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

CMV disease; Cytomegalovirus; Glycoprotein B; Glycoprotein H; Reinfection; Renal transplantation

Indexed keywords

BIOLOGICAL MARKER; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; GLYCOPROTEIN B; GLYCOPROTEIN H; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT RECIPIENT; HUMAN; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DOMAIN; RECURRENT VIRUS INFECTION; RETROSPECTIVE STUDY; SEROTYPE; VIRUS IMMUNITY;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPES; HUMANS; KIDNEY TRANSPLANTATION; SEROTYPING; SPECIES SPECIFICITY; TISSUE DONORS; VIRAL ENVELOPE PROTEINS;

EID: 79958011811     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00563.x     Document Type: Article

References (21)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
2. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001; 344: 1366-1371.
3. Ishibashi K, Tokumoto T, Tanabe K, et al. Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Clin Infect Dis 2007; 45: 60-67.
4. Burkhardt C, Himmelein S, Britt W, Winkler T, Mach M. Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. J Gen Virol 2009; 90: 1951-1961.
5. Gyulai Z, Endresz V, Burian K, et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 2000; 181: 1537-1546.
6. Meyer H, Sundqvist VA, Pereira L, Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 1992; 73 (Part 9): 2375-2383.
7. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
8. Ishibashi K, Tokumoto T, Shirakawa H, et al. Strain-specific seroepidemiology and reinfection of cytomegalovirus. Microbes Infect 2008; 10: 1363-1369.
9. Sagedal S, Nordal KP, Hartmann A, et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899-1908.
10. Terlizzi ME, Costa C, Astegiano S, et al. Monitoring of human Cytomegalovirus infection by antigenemia and viremia in the first 100 days following renal transplantation and relation to antiviral strategies. Minerva Med 2008; 99: 231-239.
11. Britt WJ, Mach M. Human cytomegalovirus glycoproteins. Intervirology 1996; 39: 401-412.
12. Rothe M, Pepperl-Klindworth S, Lang D, et al. An antigen fragment encompassing the AD2 domains of glycoprotein B from two different strains is sufficient for differentiation of primary vs. recurrent human cytomegalovirus infection by ELISA. J Med Virol 2001; 65: 719-729.
13. Messori A, Rampazzo R, Scroccaro G, Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1994; 13: 163-167.
14. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008; 22: 89-97.
15. Schoppel K, Schmidt C, Einsele H, Hebart H, Mach M. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis 1998; 178: 1233-1243.
16. Volpi A, Pica F, Gentile G, Capobianchi A, Fraschetti M, Martino P. Neutralizing antibody response against human cytomegalovirus in allogeneic bone marrow-transplant recipients. J Infect Dis 1999; 180: 1747-1748.
17. Munoz I, Gutierrez A, Gimeno C, et al. Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. J Med Virol 2001; 65: 77-84.
18. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373-1380.
19. Sester M, Sester U, Gartner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 1287-1294.
20. Elkington R, Shoukry NH, Walker S, et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol 2004; 34: 3216-3226.
21. Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77: 5226-5240.